Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping and dynamic trajectories.

Patients with sustained improvement achieved a 41.5 μmol/L decrease in creatinine concentration at 3 months, whereas patients with deterioration showed only a 7.5 μmol/L reduction, indicating a highly significant difference ( p < 0.001) ( Table 4 and Figure 2 ). 3.6.

also in 132,142 other papers